Identifying Treatments for Stage C2 Heart Failure

Clyde W. Yancy; Adrian F. Hernandez; Gregg C. Fonarow

doi:10.1001/jamacardio.2021.4024

Identifying Treatments for Stage C2 Heart Failure

Clyde W. Yancy, Adrian F. Hernandez, Gregg C. Fonarow^*

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	34-35
Number of pages	2
Journal	JAMA cardiology
Volume	7
Issue number	1
DOIs	https://doi.org/10.1001/jamacardio.2021.4024
State	Published - Jan 2022

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1001/jamacardio.2021.4024

Cite this

@article{16c1b009c8da4e498617063b07ed2cda,

title = "Identifying Treatments for Stage C2 Heart Failure",

author = "Yancy, {Clyde W.} and Hernandez, {Adrian F.} and Fonarow, {Gregg C.}",

note = "Funding Information: having a spouse who is employed by Abbott Laboratories outside the submitted work. Dr Hernandez reported receiving grants from American Regent, Boehringer Ingelheim, Merck & Co, and Verily Life Sciences and personal fees from Amgen, AstraZeneca, Bayer, Boston Scientific, and Cytokinetics outside the submitted work. Dr Fonarow reported receiving personal fees from Abbott Laboratories, Amgen, AstraZeneca, Bayer, Cytokinetics, Janssen Pharmaceuticals, Medtronic, Merck & Co, and Novartis outside the submitted work. No other disclosures were reported.",

year = "2022",

month = jan,

doi = "10.1001/jamacardio.2021.4024",

language = "English (US)",

volume = "7",

pages = "34--35",

journal = "JAMA Cardiology",

issn = "2380-6583",

publisher = "American Medical Association",

number = "1",

}

TY - JOUR

T1 - Identifying Treatments for Stage C2 Heart Failure

AU - Yancy, Clyde W.

AU - Hernandez, Adrian F.

AU - Fonarow, Gregg C.

N1 - Funding Information: having a spouse who is employed by Abbott Laboratories outside the submitted work. Dr Hernandez reported receiving grants from American Regent, Boehringer Ingelheim, Merck & Co, and Verily Life Sciences and personal fees from Amgen, AstraZeneca, Bayer, Boston Scientific, and Cytokinetics outside the submitted work. Dr Fonarow reported receiving personal fees from Abbott Laboratories, Amgen, AstraZeneca, Bayer, Cytokinetics, Janssen Pharmaceuticals, Medtronic, Merck & Co, and Novartis outside the submitted work. No other disclosures were reported.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85117229257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85117229257&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2021.4024

DO - 10.1001/jamacardio.2021.4024

M3 - Comment/debate

C2 - 34643645

AN - SCOPUS:85117229257

VL - 7

SP - 34

EP - 35

JO - JAMA Cardiology

JF - JAMA Cardiology

SN - 2380-6583

IS - 1

ER -

Identifying Treatments for Stage C2 Heart Failure

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this